Crinetics Pharmaceuticals secured FDA approval for Palsonify (paltusotine), the first once-daily oral therapy for adults with acromegaly who have had inadequate response to surgery or are not candidates for surgery. This priority review approval introduces a convenient alternative to existing injectable treatments from Novartis and Ipsen, potentially reshaping acromegaly management. The drug’s approval reflects an advance in managing a rare endocrine disorder characterized by excessive growth hormone production.